These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25486409)

  • 21. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.
    Li K; Zhou F; Zhou Y; Zhang S; Li Q; Li Z; Liu L; Wu G; Meng R
    Int J Mol Med; 2019 Aug; 44(2):437-446. PubMed ID: 31173177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
    Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
    Kim HP; Han SW; Kim SH; Im SA; Oh DY; Bang YJ; Kim TY
    Mol Cancer Ther; 2008 Mar; 7(3):607-15. PubMed ID: 18347147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
    Nihira K; Miki Y; Iida S; Narumi S; Ono K; Iwabuchi E; Ise K; Mori K; Saito M; Ebina M; Sato I; Maemondo M; Yamada-Okabe H; Kondo T; Sasano H
    J Pathol; 2014 Oct; 234(2):277-88. PubMed ID: 24687913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells.
    Sakuma Y; Matsukuma S; Nakamura Y; Yoshihara M; Koizume S; Sekiguchi H; Saito H; Nakayama H; Kameda Y; Yokose T; Oguni S; Niki T; Miyagi Y
    Lab Invest; 2013 Oct; 93(10):1137-46. PubMed ID: 23938604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.
    Sakuma Y; Nishikiori H; Hirai S; Yamaguchi M; Yamada G; Watanabe A; Hasegawa T; Kojima T; Niki T; Takahashi H
    Lab Invest; 2016 Apr; 96(4):391-8. PubMed ID: 26752745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.
    Harada D; Takigawa N; Ochi N; Ninomiya T; Yasugi M; Kubo T; Takeda H; Ichihara E; Ohashi K; Takata S; Tanimoto M; Kiura K
    Cancer Sci; 2012 Oct; 103(10):1795-802. PubMed ID: 22712764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells.
    Yang Z; Hu X; Zhang S; Zhang W; Tam KY
    Eur J Pharmacol; 2017 Nov; 815():80-87. PubMed ID: 28870456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
    Zhang X; Belkina N; Jacob HK; Maity T; Biswas R; Venugopalan A; Shaw PG; Kim MS; Chaerkady R; Pandey A; Guha U
    Proteomics; 2015 Jan; 15(2-3):340-55. PubMed ID: 25404012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
    Pirazzoli V; Ayeni D; Meador CB; Sanganahalli BG; Hyder F; de Stanchina E; Goldberg SB; Pao W; Politi K
    Clin Cancer Res; 2016 Jan; 22(2):426-35. PubMed ID: 26341921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
    Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.
    So KS; Rho JK; Choi YJ; Kim SY; Choi CM; Chun YJ; Lee JC
    Anticancer Res; 2015 Mar; 35(3):1537-42. PubMed ID: 25750308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.